BMH2 Antibody

What is MSH2 protein and why is it important in biomedical research?

MSH2 (MutS Homolog 2) is a critical protein involved in DNA mismatch repair mechanisms. Its significance in biomedical research stems from its role in maintaining genomic stability. Mutations in the MSH2 gene have been identified in a large proportion of hereditary non-polyposis colorectal cancer (Lynch Syndrome), which is the most common form of inherited colorectal cancer in Western populations . Additionally, MSH2 mutations have been associated with various sporadic tumors, making it an important target for cancer research. When designing experiments involving MSH2, researchers should consider its molecular weight (approximately 100 kDa) and its predominant nuclear localization in cells with active DNA replication and repair.

What applications are supported by commercially available MSH2 antibodies?

MSH2 antibodies support multiple research applications with varying recommended dilutions as shown in the following table:

These applications enable researchers to study MSH2 expression, localization, and interactions across multiple experimental contexts . When selecting an application, consider the specific research question and available sample types, as each method has distinct advantages and limitations for MSH2 detection.

How should I validate MSH2 antibody specificity for my particular experimental system?

Antibody validation is critical for reliable research outcomes. For MSH2 antibody validation, follow the "five pillars" approach recommended by the International Working Group for Antibody Validation :

• Genetic strategies: Use MSH2 knockout or knockdown cell lines as negative controls to confirm antibody specificity.

• Orthogonal strategies: Compare antibody-based MSH2 detection with antibody-independent methods (e.g., mass spectrometry or RNA-seq).

• Multiple antibody strategy: Test independent antibodies targeting different MSH2 epitopes to confirm consistent results.

• Recombinant expression: Overexpress MSH2 to verify signal increase proportional to expression levels.

• Immunocapture-MS: Use mass spectrometry to identify proteins captured by the MSH2 antibody to confirm target specificity.

Documentation should confirm that: (i) the antibody binds to MSH2; (ii) it recognizes MSH2 in complex protein mixtures; (iii) it lacks cross-reactivity with non-target proteins; and (iv) it performs consistently in your specific experimental conditions .

How can I optimize MSH2 antibody performance for detecting low protein expression in clinical samples?

Detecting low MSH2 expression levels in clinical samples requires optimization beyond standard protocols:

• Signal amplification: Implement tyramide signal amplification (TSA) for immunohistochemistry to enhance sensitivity by up to 100-fold.

• Epitope retrieval optimization: For formalin-fixed paraffin-embedded (FFPE) samples, test both heat-induced epitope retrieval (HIER) and enzymatic retrieval methods at multiple pH values (6.0, 8.0, 9.0) to determine optimal conditions.

• Blocking optimization: Use a combination of serum, BSA, and casein blockers to reduce background while preserving specific signal.

• Extended antibody incubation: Consider overnight incubation at 4°C at higher concentration (1:100) for IHC applications to improve binding kinetics.

• Signal-to-noise ratio enhancement: Implement dual detection systems with complementary visualization methods.

For western blotting of low-abundance MSH2, consider sample enrichment through immunoprecipitation prior to SDS-PAGE and optimize exposure times using highly sensitive chemiluminescent substrates with sequential imaging at multiple timepoints.

What are the best experimental controls when using MSH2 antibodies for research in cancer models?

Robust controls are essential for MSH2 antibody experiments in cancer research:

• Positive tissue controls: Include colorectal cancer cell lines with known MSH2 expression (e.g., HCT116) as positive controls.

• Negative tissue controls: Use matched MSH2-deficient cell lines or tissues from Lynch Syndrome patients with confirmed MSH2 mutations.

• Peptide competition: Pre-incubate antibody with synthetic MSH2 peptide corresponding to the epitope to confirm binding specificity.

• Isotype controls: Use matched isotype antibody at identical concentration to identify non-specific binding.

• Heterogeneous sample controls: Include tissues with varying MSH2 expression levels to validate dynamic range.

For Lynch Syndrome research, paired normal/tumor tissue samples should be processed simultaneously to assess differential MSH2 expression within the same experimental run, minimizing batch effects that could confound interpretation .

How can I address discrepancies between MSH2 protein detection by antibody-based methods versus mRNA expression data?

Discrepancies between MSH2 protein and mRNA levels are common and can stem from multiple factors:

• Post-transcriptional regulation: Assess microRNA regulation of MSH2 by correlating expression of known MSH2-targeting miRNAs with protein levels.

• Protein stability assessment: Measure MSH2 half-life using cycloheximide chase assays to evaluate if protein turnover contributes to discrepancies.

• Alternative splicing analysis: Use isoform-specific primers for RT-PCR alongside antibodies targeting different MSH2 epitopes to identify splice variants.

• Technical variation evaluation:

  • Perform spike-in controls with recombinant MSH2 for protein quantification

  • Use absolute quantification methods for mRNA (droplet digital PCR)

  • Standardize sample preparation and normalization methods

• Integrated multi-omics approach: Apply proteogenomic analysis correlating RNA-seq with mass spectrometry-based protein quantification to resolve discrepancies.

When reporting such discrepancies, document all experimental conditions, sample preparation methods, and normalization strategies to enable proper interpretation of biological versus technical variance .

What are the advantages and limitations of monoclonal versus polyclonal MSH2 antibodies for different applications?

Both antibody types offer distinct advantages and limitations for MSH2 detection:

Recent data from YCharOS and Abcam using knockout cell lines demonstrate that recombinant monoclonal antibodies are significantly more effective and reproducible than polyclonal antibodies for MSH2 detection . The XP® Rabbit mAb (D24B5) offers superior lot-to-lot consistency and specificity for MSH2, particularly for applications requiring quantitative analysis .

How should I optimize extraction conditions to preserve MSH2 protein integrity for immunodetection?

MSH2 protein preservation requires careful optimization of extraction conditions:

• Buffer composition:

  • Use RIPA buffer supplemented with 1% NP-40 for total protein extraction

  • For nuclear extraction, use hypotonic buffer followed by high-salt nuclear extraction

  • Add protease inhibitors (complete cocktail) to prevent degradation

  • Include phosphatase inhibitors if studying MSH2 phosphorylation status

• Physical disruption method:

  • For cell lines: Gentle sonication (3-5 pulses of 10 seconds)

  • For tissues: Mechanical homogenization at 4°C followed by brief sonication

• Temperature control:

  • Maintain samples at 4°C throughout processing

  • Avoid repeated freeze-thaw cycles (limit to maximum of two)

• Denaturing conditions:

  • For western blotting, heat samples at 95°C for 5 minutes in Laemmli buffer

  • For immunoprecipitation, use native conditions (avoid SDS and reducing agents)

• Storage conditions:

  • Store extracted protein at -80°C with 10% glycerol

  • Aliquot samples to minimize freeze-thaw cycles

These optimized conditions help maintain MSH2 structural integrity and epitope accessibility, improving detection reliability across experimental applications.

What methodological approaches can detect post-translational modifications of MSH2 using antibodies?

Detection of MSH2 post-translational modifications (PTMs) requires specialized techniques:

• Phospho-specific antibodies:

  • Use phospho-site specific antibodies for known MSH2 phosphorylation sites

  • Validate with lambda phosphatase treatment as negative control

  • Include positive controls (cells treated with DNA damaging agents)

• Two-dimensional western blotting:

  • Separate proteins by isoelectric point followed by molecular weight

  • Compare patterns before and after phosphatase treatment

  • Use general MSH2 antibody for detection

• Ubiquitination detection:

  • Co-immunoprecipitate MSH2 under denaturing conditions

  • Probe with anti-ubiquitin antibodies

  • Include proteasome inhibitors (MG132) during extraction

• Mass spectrometry validation:

  • Immunoprecipitate MSH2 and analyze by LC-MS/MS

  • Use neutral loss scanning to detect phosphorylation sites

  • Implement SILAC labeling for quantitative PTM analysis

• Proximity ligation assay (PLA):

  • Detect interaction between MSH2 and PTM-specific antibodies

  • Provides spatial information about modified MSH2 in cells

  • Controls should include PTM-blocking treatments

These approaches enable detection of functionally relevant MSH2 modifications that may alter its DNA repair capacity or protein-protein interactions in cancer models.

How can I address non-specific binding when using MSH2 antibodies in western blotting or immunohistochemistry?

Non-specific binding is a common challenge with MSH2 antibodies that can be addressed through systematic optimization:

• For western blotting:

  • Increase blocking stringency (5% milk or BSA for 2 hours)

  • Optimize primary antibody dilution (test range from 1:500 to 1:5000)

  • Increase washing duration and detergent concentration (0.1% to 0.3% Tween-20)

  • Use MSH2 knockout lysates to identify non-specific bands

  • Try alternative blocking agents (casein, fish gelatin) if milk/BSA are ineffective

• For immunohistochemistry/immunofluorescence:

  • Pre-absorb secondary antibodies with tissue powder

  • Include 0.1-0.3% Triton X-100 in antibody diluent

  • Implement dual blocking strategy (serum followed by protein block)

  • Titrate primary antibody concentration

  • Use antigen adsorption controls to identify non-specific staining

• General approaches:

  • Test alternative antibody clones targeting different MSH2 epitopes

  • Use recombinant antibody formats for improved specificity

  • Include appropriate negative controls (isotype, peptide competition)

These approaches address the ~50% failure rate of commercial antibodies to meet basic specificity standards, which costs the research community between $0.4–1.8 billion annually in the US alone .

What criteria should be used to evaluate new MSH2 antibody lots for experimental consistency?

Lot-to-lot variation significantly impacts experimental reproducibility. Implement these validation steps for each new MSH2 antibody lot:

• Direct comparison testing:

  • Run side-by-side western blots with old and new lots

  • Calculate signal-to-noise ratios and compare band intensities

  • Assess background staining patterns

• Quantitative assessment:

  • Establish standard curves using recombinant MSH2 protein

  • Calculate detection limits and linear range for each lot

  • Document EC50 values for binding assays

• Cross-application validation:

  • Test performance in all intended applications (WB, IP, IHC, IF)

  • Document optimal dilutions for each application

  • Evaluate epitope accessibility in different sample preparations

• Reference sample testing:

  • Maintain frozen aliquots of reference samples for lot testing

  • Include positive and negative controls with established signal intensities

  • Document imaging parameters required for equivalent signal detection

• Specificity confirmation:

  • Verify absence of signal in knockout/knockdown samples

  • Confirm expected molecular weight (100 kDa for MSH2)

  • Test cross-reactivity with related MutS homologs

Standardized validation protocols are essential to address the problem that ~50% of commercial antibodies fail to meet even basic standards for characterization .

How can I integrate MSH2 antibody-based analyses with other detection methods for comprehensive protein characterization?

Multi-modal MSH2 characterization provides robust validation through orthogonal approaches:

• Integrated antibody and transcript analysis:

  • Correlate protein levels (western blot/IHC) with mRNA expression (qPCR/RNA-seq)

  • Document concordance/discordance between protein and mRNA levels

  • Analyze potential regulatory mechanisms when discrepancies exist

• Mass spectrometry integration:

  • Perform immunoprecipitation followed by MS analysis (IP-MS)

  • Identify MSH2 interaction partners and post-translational modifications

  • Validate antibody specificity through peptide identification

• Functional assays:

  • Correlate MSH2 protein levels with mismatch repair activity assays

  • Assess MSH2-dependent protein complex formation

  • Measure DNA damage response in relation to MSH2 expression

• Imaging correlation:

  • Combine immunofluorescence with proximity ligation assays (PLA)

  • Correlate subcellular localization with interaction partners

  • Implement FRET-based approaches to assess protein proximity

• Single-cell analysis:

  • Integrate flow cytometry with single-cell RNA-seq

  • Correlate protein abundance with transcript levels at single-cell resolution

  • Assess heterogeneity in MSH2 expression across cell populations

This integrated approach aligns with recommendations from the International Working Group for Antibody Validation, which advocates for orthogonal strategies to enhance reproducibility in antibody-based research .

How can recombinant antibody technologies improve MSH2 detection and experimental reproducibility?

Recombinant antibody technologies offer significant advantages for MSH2 research:

• Enhanced reproducibility:

  • Recombinant antibodies provide superior lot-to-lot consistency compared to hybridoma-derived or polyclonal antibodies

  • DNA sequence-defined production eliminates batch variation inherent to animal immunization

  • Standardized expression systems ensure consistent glycosylation and post-translational modifications

• Engineered specificity:

  • Affinity maturation through directed evolution can improve MSH2 binding by up to 50-fold

  • DyAb sequence-based design can achieve Spearman rank correlations of up to 0.85 for binding affinity predictions

  • Epitope engineering can target conserved MSH2 regions for cross-species applications

• Format flexibility:

  • Single-chain variable fragments (scFvs) enable better tissue penetration

  • Bi-specific formats allow simultaneous detection of MSH2 and interaction partners

  • Intrabody formats permit live-cell imaging of MSH2 dynamics

• Application-specific optimization:

  • Humanized formats reduce background in human tissue applications

  • Isotype switching enables application-specific secondary detection

  • Fragment-based formats eliminate Fc-mediated artifacts

Recent demonstration by YCharOS and Abcam using knockout cell lines showed that recombinant antibodies were more effective than polyclonal antibodies and far more reproducible for target protein detection , making them the preferred choice for critical MSH2 research applications.

What considerations are important when designing multiplex experiments that include MSH2 antibody detection?

Multiplex experimental design with MSH2 antibodies requires careful optimization:

• Antibody compatibility assessment:

  • Test for cross-reactivity between primary and secondary antibodies

  • Validate epitope accessibility in multiplexed staining conditions

  • Ensure primary antibodies are from different host species or isotypes

• Signal separation strategies:

  • Implement spectral unmixing for fluorescent detection systems

  • Use sequential detection for chromogenic multiplex IHC

  • Consider tyramide signal amplification (TSA) with sequential rounds of staining

• Controls for multiplex experiments:

  • Include single-stain controls for each antibody

  • Perform antibody omission controls to assess cross-reactivity

  • Use biological reference samples with known expression patterns

• Sample preparation optimization:

  • Evaluate fixation impact on multiple epitopes simultaneously

  • Optimize antigen retrieval conditions that preserve all targets

  • Test order dependency of antibody application

• Data analysis considerations:

  • Implement spectral compensation matrices for fluorescent multiplex

  • Consider colocalization analysis for protein interaction studies

  • Apply machine learning algorithms for pattern recognition in complex datasets

Successful multiplex detection enables simultaneous analysis of MSH2 with other DNA repair proteins or pathway components, providing insights into functional relationships that single-target approaches cannot reveal.

How can I adapt MSH2 antibody-based detection methods for high-throughput screening applications?

Adaptation of MSH2 detection for high-throughput screening requires systematic optimization:

• Assay miniaturization:

  • Scale protocols to 384 or 1536-well formats

  • Optimize antibody concentrations for reduced volumes (1-5 μL/well)

  • Implement automated liquid handling for consistent reagent delivery

• Signal detection optimization:

  • Select high-sensitivity fluorescent conjugates for detection

  • Establish optimal signal-to-background ratios for automated image analysis

  • Determine Z'-factor for assay quality assessment (aim for >0.5)

• Workflow automation:

  • Develop automated protocols for cell fixation and antibody staining

  • Implement barcode tracking systems for sample identification

  • Establish parallel processing for multiple plate handling

• Data analysis pipelines:

  • Develop automated image analysis algorithms for MSH2 quantification

  • Implement quality control metrics for assay performance monitoring

  • Design multiparametric readouts (e.g., MSH2 levels, nuclear localization, complex formation)

• Validation strategies:

  • Include positive/negative controls in each plate

  • Establish dose-response relationships for reference compounds

  • Implement replicate testing strategies for hit confirmation

These optimization steps enable screening applications such as drug discovery targeting MSH2-dependent DNA repair pathways, genetic modifier screens affecting MSH2 function, or compound libraries affecting MSH2 stability and localization in cancer models.